Wolfgang Froestl Selected Research

GABA-B Receptor Agonists

5/2011	Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats.
3/2011	Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.
1/2010	Chemistry and pharmacology of GABAB receptor ligands.
3/2004	The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat.
2/2001	The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Froestl Research Topics

Disease

10	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 01/2012
4	Schizophrenia (Dementia Praecox) 01/2013 - 08/2010
3	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2013 - 01/2012
3	Stroke (Strokes) 01/2013 - 01/2012
3	Substance-Related Disorders (Drug Abuse) 05/2011 - 03/2004
3	Tobacco Use Disorder (Nicotine Dependence) 05/2011 - 12/2005
3	Hypothermia 08/2010 - 11/2003
2	Alcoholism (Alcohol Abuse) 08/2012 - 11/2005
2	Cocaine-Related Disorders (Cocaine Addiction) 11/2005 - 04/2004
1	Amyloidosis 01/2014
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2011
1	Chronic Pain 08/2010
1	Gastroesophageal Reflux (GERD) 01/2010
1	Ataxia (Dyssynergia) 07/2005
1	Narcolepsy 07/2005
1	Tremor (Tremors) 05/2005
1	Cognitive Dysfunction 10/2004
1	Stupor 09/2004
1	succinic semialdehyde dehydrogenase deficiency 07/2002
1	Hyperalgesia 02/2001
1	Pain (Aches) 02/2001

Drug/Important Bio-Agent (IBA)

8	GABA-B ReceptorsIBA 05/2011 - 07/2002
6	Nootropic Agents (Nootropics)IBA 01/2014 - 01/2012
5	Baclofen FDA LinkGeneric 08/2012 - 02/2001
5	GABA-B Receptor AgonistsIBA 05/2011 - 02/2001
5	Nicotine FDA Link 05/2011 - 12/2005
3	Peptides (Polypeptides)IBA 01/2017 - 10/2012
3	Amyloid (Amyloid Fibrils)IBA 01/2017 - 01/2014
3	(3-aminopropyl)(n-butyl)phosphinic acidIBA 07/2005 - 10/2004
2	Cocaine (Cocaine HCl)IBA 08/2010 - 01/2010
2	N,N'- dicyclopentyl- 2- methylsulfanyl- 5- nitro- pyrimidine- 4,6- diamineIBA 01/2010 - 09/2004
2	NCS 382IBA 07/2005 - 07/2002
2	gamma-Aminobutyric Acid (GABA)IBA 03/2004 - 02/2001
1	indoleIBA 01/2017
1	7-azaindole dimerIBA 01/2017
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2014
1	2,6- di- tert- butyl- 4- (3- hydroxy- 2,2- dimethylpropyl)phenolIBA 01/2010
1	Heroin (Diamorphine)IBA 01/2010
1	N- (bicyclo(2.2.1)hept- 2- yl)- 2- methyl- 5- (4- (trifluoromethyl)phenyl)- 4- pyrimidinamineIBA 01/2010
1	lesogaberanIBA 01/2010
1	Morphine (MS Contin)FDA LinkGeneric 01/2010
1	arbaclofen placarbilIBA 01/2010
1	ProdrugsIBA 01/2010
1	Pharmaceutical PreparationsIBA 07/2005
1	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 07/2005
1	BenzodiazepinesIBA 09/2004
1	Chlordiazepoxide (Elenium)FDA LinkGeneric 09/2004
1	Dopamine (Intropin)FDA LinkGeneric 11/2003
1	Vigabatrin FDA Link 07/2002
1	Succinate-Semialdehyde Dehydrogenase (Succinic Semialdehyde Dehydrogenase)IBA 07/2002
1	Taurine FDA Link 07/2002
1	Gabapentin (Neurontin)FDA LinkGeneric 02/2001

Therapy/Procedure

2	Therapeutics 01/2014 - 05/2011
2	Drug Therapy (Chemotherapy) 11/2005 - 04/2004
1	Oral Administration 10/2004
1	Ligation 02/2001